EML4-ALK融合基因与非小细胞肺癌分子靶向治疗的研究现况
被引量:1
摘要
肺癌是当今世界最常见的恶性肿瘤之一。据统计,每年新发肺癌患者中有大约85%为非小细胞肺癌,而其中又有70%的患者在确诊时已存在局部晚期或远处转移[1]。近年来随着对癌症发病机制的深入研究和分子生物学的发展,出现了以特定分子为靶点的抗肿瘤药物。针对EGFR19或21号外显子突变而开发的酪氨酸激酶抑制剂,
出处
《临床肺科杂志》
2013年第5期907-909,共3页
Journal of Clinical Pulmonary Medicine
参考文献28
-
1Jemal A, Center MM, Dcsantis C, et al. Global patterns of cancer incidence and mortality rates and trends[ J]. Cancer Epidemiol Bio- markers Prev, 2010,19 : 1893 - 1907.
-
2Mok TS, Wu YL, Thongprasert S. Phase m, randomised, openla- bel, first-line study of gefitinib vs carboplatin/paclitaxel in clinical- ly selected patients with advanced nonsmall-cell lung cancer (IPASS) [J]. in ESMO Confe 2008, Stockholm.
-
3Palmer RH, Vernersson E, Grabbe C, et al. Anaplastic lymphoma kinase: signaling in development and disease [ J ]. Biochem J, 2009,420:345 - 361.
-
4Camidge DR, Bang Y, Kwak EL, et al. Progression-Free Survival (PFS) from a Phase 1 Study of Crizotinib (PF-02341066) in Pa- tients with ALK-Positive Non-Small Cell Lung Cancer (NSCLC) [J]. in ASCO, 2011, Chicago.
-
5Crino L, Kim D, Riely GJ, et al. Initial phase II results with erizo- tinib in advanced ALK-positive non-small cell lung cancer (NSCLC) : Profile 1005, in Aseo, 2011, Chicago. Soda M, Choi YL, Enomoto M, et al. Identification of the transfor- ming EMIA-ALK fusion gene in non small cell lung cancer[ J]. Na- ture, 2007,448(7153): 561 -566.
-
6Crino L, Kim D, Riely GJ, et al. Initial phase II results with crizo- tinib in advanced ALK-positive non-small cell lung cancer (NSCLC) : Profile 1005, in Asco, 2011, Chicago. Soda M, Choi YL, Enomoto M, et al. Identification of the transfor- ming EMIA-ALK fusion gene in non small cell lung cancer[ J]. Na- ture, 2007,448(7153): 561 -566.
-
7Takeuehi K, Choi YL, Togashi Y, et al. KIF5B-ALK, a novel fu- sion oncokinase identified by an immunohistochemistry-based diag- nostic system for ALK-positive lung cancer [ J ]. Clin Cancer Res, 2009,15:3143 - 3149.
-
8Koivunen JP, Mermel C, Zejnullahu K, et al. EML4. ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer[ J ]. Clin Cancer Res, 2008, 14(13) : 4275 -4283.
-
9Pemer S, Wagner PL, Demichelis F, et al. EMIA-ALK fusion lung cancer : a rare acquired event [ J ]. Neoplasia, 2008,10:298 - 302.
-
10Wang DW, Leung EL, So KK, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmok- ers with wild-type EGFR and KRAS[ J]. Cancer, 2009,115 : 1723 - 1733.
同被引文献11
-
1邬方宁.参麦注射液的抗肿瘤作用研究[J].现代药物与研究,2013,28(1):21-24.
-
2Kuss I, Hathway B, Ferris RL, et al. Decreased absolut counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck[ J]. Clin Cancer Res, 2004,10 ( 11 ) : 3755 - 3762.
-
3Sabine VS, Faratian D, Kirkegaard-Clausen T, et al. Validation of activated caspase-3 antibody staining as a marker of apoptosis in breast cancer[J]. Histopathology 2012, 60:369 - 371.
-
4Li s, Tian D, Fei P, et al. A cyclooxygase-2 inhibitor NS-398-en- hanced apoptosis of esophageal carcinoma cell EC9706 by adjus- ting expression of survivin and caspase-3 [ J]. Cancer Invest, 2011,29:102 - 106.
-
5孟凡亮,胡杰贵,李自生.血清TPS,CEA,CYF RA2 1-1,NSE联合检测对肺癌的诊断价值[J].临床肺科杂志,2011,16(2):223-225. 被引量:12
-
6蒋晓东,戴鹏,宋大安,吴瑾,黎世秋.HIF-1α、VEGF、VEGFR2在非小细胞肺癌组织中的表达及临床意义[J].临床肺科杂志,2011,16(3):386-388. 被引量:62
-
7王伟,姚朝辉.生脉注射液对晚期非小细胞肺癌患者化疗毒副反应及免疫功能的影响[J].临床肺科杂志,2012,17(5):876-877. 被引量:18
-
8朱洪斌,程赛利.参麦注射液联合EP方案治疗局限期小细胞肺癌的疗效观察[J].临床肺科杂志,2012,17(12):2255-2256. 被引量:9
-
9王国利,李景武.Clusterin、Livin、和P53在胃癌中的表达及意义[J].中国医药导报,2012,9(32):20-22. 被引量:5
-
10姜涛,战炳炎.TNF-α,Ang-1,IL-8在COPD合并肺动脉高压发病机制中的作用[J].临床肺科杂志,2013,18(4):585-586. 被引量:8
二级引证文献7
-
1吴贞,丁纪元,沈虹,于卓.参麦注射液辅助化疗对恶性肿瘤患者急性时相蛋白及细胞免疫功能的影响[J].中国中医药科技,2015,22(6):611-613. 被引量:10
-
2章激,田艳,薛瑞.参麦注射液体外诱导骨肉瘤MG-63细胞凋亡的机制研究[J].中医药导报,2016,22(22):28-31. 被引量:3
-
3张磊,常青,李艳,许会静,侯毅鞠.参麦注射液对肺腺癌耐药细胞株的逆转作用[J].基因组学与应用生物学,2016,35(12):3268-3272. 被引量:3
-
4郭占芳,张红武,杨如意,孙兆,刘永萍.益气复脉对中晚期肺癌患者免疫功能和生存质量的影响[J].中国现代医学杂志,2017,27(6):88-92. 被引量:14
-
5杨冬梨,徐宗佩,李玉红,李菁浩,王宏波,李琳.参麦注射液抗阿霉素心脏毒性及其协同放化疗抗肿瘤的作用[J].天津中医药大学学报,2018,37(6):445-448. 被引量:7
-
6蔡亚军,姚仲彩,皮文妍.参麦注射液联合化疗对肺癌合并肝硬化患者ALB、PAB及LMR的影响[J].广东医学,2020,41(10):1047-1050. 被引量:7
-
7聂敏.参麦注射液在癌因性疲乏中的应用[J].世界最新医学信息文摘,2018,0(62):104-105. 被引量:2
-
1华胸怀,张瑞祥,李印.EGFR基因突变与非小细胞肺癌分子靶向治疗的研究现况[J].临床肺科杂志,2012,17(1):117-119. 被引量:17
-
2阮绪芝,严世荣.胃部组织中RB基因17,21外显子突变的分析[J].癌症,1999,18(4):468-469.
-
3Faber,LP,宋礼章.非小细胞肺癌的新辅助治疗现况[J].国外防痨与肺部疾病,1995(2):26-29.
-
4黄平.单克隆抗体诊治白血病和肿瘤的现况和展望[J].临床血液学杂志,1991,4(4):185-186.
-
5邱辉忠.低位直肠癌保肛手术的现况[J].中国肛肠病杂志,1997,17(6):36-37. 被引量:33
-
6楼方定.难治性和复发性骨髓瘤治疗现况[J].中华血液学杂志,1990,11(7):382-383. 被引量:1
-
7郭仁宣.胆囊癌综合治疗的现况[J].中国实用外科杂志,1997,17(9):532-534. 被引量:9
-
8李桂生,杨春旭.肺癌,肝癌的电化学治疗现况[J].广西医学,1996,18(2):137-140. 被引量:1
-
9安子元,Reed WD.胰腺癌的现况[J].山西医药杂志,1991,20(4):234-235.
-
10川崎诚治,汤新强.肝癌的治疗现况[J].国外医学(肿瘤学分册),1992,19(1):41-42.